Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy with a poor prognosis for patients. Disulfidptosis response-related long non-coding RNAs (DRLs) have been demonstrated to be closely associated with cancer development. Therefore, this study aims to construct a prognostic DRL signature and investigate the immune microenvironment for AML. RNA-seq and clinical data for AML patients were obtained from The Cancer Genome Atlas (TCGA) database. A total of 344 disulfidptosis-associated lncRNAs were identified, and a prognostic model consisting of seven lncRNAs was constructed and validated. Two risk groups, high-risk and low-risk, were identified. The model demonstrated a robust capacity to predict prognosis, with a worse overall survival for patients in the high-risk group. Additionally, differential expression of the seven lncRNAs were relatively higher in AML samples than in control samples via quantitative polymerase chain reaction(qPCR). The Kyoto Encyclopedia of Genes and Genomes (KEGG) and immune infiltration analysis revealed a substantial infiltration of immune cells and enrichment of immune pathways in the high-risk group. The sensitivity of AML patients to drugs varied according to their risk grade. This study identified a DRL signature, which can effectively predict the prognosis of AML and better understand the mechanism of disulfidptosis in AML. This provides a basis for personalized immunotherapy in AML patients.
© 2025. The Author(s).